Chickenpox

Steril-Aire Marks 30 Years Since Pioneering the Use of UVC For HVAC®

Retrieved on: 
Friday, April 12, 2024
Education, Administration, Mutation, EPA, Government agency, Measles, Hospital, Bioterrorism, Nursing, CDC, School, Bacteria, Research, ASHRAE, Federal Emergency Management Agency, Dick Fencl, Knowledge, Engineering, Mumps, Virus, Airport, UVC, Atmosphere, Tuberculosis, Longevity, HVAC, COVID-19, UV, Chickenpox

VALENCIA, Calif., April 12, 2024 /PRNewswire-PRWeb/ -- Steril-Aire will celebrate 30 years of success this year by highlighting the key innovations that have spurred the ultraviolet disinfection industry's growth, beginning with introducing and later patenting the application of UVC for HVAC® to evaporator coils. The manufacturer is responsible for 17 technical patents that still define the HVAC ultraviolet air and surface treatment industry.

Key Points: 
  • Steril-Aire marks 30 years since it pioneered the use of UVC for HVAC® to enhance HVAC coil-heat-transfer efficiency.
  • For nearly a century, short-wave ultraviolet UVC energy—similar to sunlight—has been used to destroy airborne and surface-bound microbes, including chickenpox, measles, mumps, tuberculosis, and cold viruses.
  • In the 1940s, many hospitals and some schools began using UVC energy to control airborne infectious diseases.
  • Demand for UVC air treatment solutions truly exploded following the outbreak of the COVID-19 pandemic, according to Dan Jones, President of Steril-Aire.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.

AMERICAN ACADEMY OF DERMATOLOGY: HOW TO CHECK FOR BEDBUGS

Retrieved on: 
Thursday, March 14, 2024
Biting, Skin infection, Chickenpox, Human, Anxiety, Seed, Thought, Rash, Skin, Allergy, FAAD, AAD, Blood, Bed bug, Frustration, Blister, Nail, Spider, Bed, Baggage

ROSEMONT, Ill., March 14, 2024 /PRNewswire/ -- Bedbugs can make you itch just by thinking about them. These tiny, reddish-brown insects that feed on blood are notorious for infiltrating hotel rooms and luggage, hitchhiking their way back to a new home virtually undetected.

Key Points: 
  • Although bedbug bites are not usually dangerous, bedbugs can come home with you, infest your home, and cause a great deal of discomfort and anxiety.
  • If bedbugs are present in your home, you will likely find bites on your body.
  • There are fewer spots for bedbugs to hide in bathrooms, so you can check your room without worry.
  • These tips are demonstrated in " How to check for bedbugs ," a video posted to the AAD website and YouTube channel .

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Chills, Patient, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Fever, Fatigue, Shingles, Human, ATC, Antibody, Bone marrow, Pain, Chronic pain, International, Injection, Headache, Disease, Ageing, Nausea, Language, HZ, Vaccination, Swelling, Red, PHN, Trigeminal neuralgia, European Medicines Agency, Chickenpox, Myalgia, Select, Anatomy, Vomiting, IIA, Vaccine

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Microbix & BioGX Collaborate on real-time PCR Assays & Controls

Retrieved on: 
Thursday, December 7, 2023
Herpes simplex, Chickenpox, Mpox, OTCQX, Collection, Business, Applied Biosystems, PCR, Syphilis, Refrigeration, COVID, Business development, SARS-CoV-2, TSX, SVP, Pleasure, XFree86, Treponema pallidum

Microbix was chosen by BioGX to be the primary External Quality Controls provider for assays on their newly-launched pixl platform – a benchtop instrument with capabilities for syndromic testing.

Key Points: 
  • Microbix was chosen by BioGX to be the primary External Quality Controls provider for assays on their newly-launched pixl platform – a benchtop instrument with capabilities for syndromic testing.
  • Microbix QAPs are now referenced in BioGX Assay Product Inserts (available at https://www.biogx.com ), with additional QAPs to be referenced as the collaboration expands.
  • Xfree technology provides a complete lyophilized test in a single tube – using the trusted BioGX Sample-Ready™ format for extraction-free, direct sample addition in real-time PCR testing.
  • Phil Casselli, SVP of Sales & Business Development at Microbix, commented, “It has been a pleasure to work with Robert and his team at BioGX to support their customer base with robust External Quality Controls.

United States INVELTYS (Loteprednol Etabonate/KPI-121) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Health, Pharmaceutical, Eye, AOP, Research, Conjunctiva, Clinical trial, SWOT, Vaccinia, Pain, Chickenpox, Inflammation, Dietary supplement, Pharmaceutical industry, Telescopic sight

This report provides comprehensive insights about INVELTYS for acute ocular pain (AOP) in the United States.

Key Points: 
  • This report provides comprehensive insights about INVELTYS for acute ocular pain (AOP) in the United States.
  • A detailed picture of the INVELTYS for acute ocular pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the INVELTYS for acute ocular pain.
  • Further, it also consists of future market assessments inclusive of the INVELTYS market forecast analysis for acute ocular pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.
  • This report provides a detailed market assessment of INVELTYS for acute ocular pain in the United States.

United States INVELTYS (Loteprednol Etabonate/KPI-121) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Health, Pharmaceutical, Eye, Research, Viral, Pain, Conjunctiva, Collagen, SWOT, Edema, Vaccinia, Glucocorticoid, Chickenpox, Inflammation, Poultry farming, Dietary supplement, Pharmaceutical industry

The "United States INVELTYS Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States INVELTYS Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about INVELTYS for acute pain in the United States.
  • A detailed picture of the INVELTYS for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the INVELTYS for acute pain.
  • This report provides a detailed market assessment of INVELTYS for acute pain in the United States.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Contact, Ernest, Cerebral edema, Palace, Employment, Pain, Telecanthus, Incidence, Hilton New Orleans Riverside, Steroid, Viral, Macular edema, Herpes simplex, NYSE, Chickenpox, Magazine Street, Canal Street, Conjunctiva, EYE, Tchoupitoulas Street, Risk, Pigment, Intraocular pressure, SM, Optic nerve, FDA, INA War Museum, Iris, Andhra Pradesh Decentralisation and Inclusive Development of All Regions Act, 2020, Fungal infection, Poydras Street, Sclera, Eye, Bausch, History, Slit lamp, Glaucoma, Ocular hypertension, DED, Cornea, IOP, Contact lens, Infection, American Academy, Inflammation, Johnson & Johnson Vision, Vaccinia, Bausch & Lomb, Lens (vertebrate anatomy), Visual acuity, Pharmaceutical industry, Medical device, Hospital, Telescopic sight, Hotel, Gasoline, Nursing, Dietary supplement, Vaccine, Blinking, O.D, Patient

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.